{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-185058","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.980837+00:00","generated_at":"2026-06-24T22:28:05.635710+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease","bullets":["Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.","Phase 2/3 adaptive trial (EBO-301) targets ~314 patients; Phase 2 topline expected mid-2023, Phase 3 mid-2024.","Epetraborole has FDA QIDP, Fast Track, and Orphan Drug designations; plans to use LPAD pathway for streamlined approval.","First patient screened; Phase 2 will assess clinical response, safety, and PK to inform Phase 3 design."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-185058","json":"https://secwatch.observer/filing/0001193125-22-185058.json","markdown":"https://secwatch.observer/filing/0001193125-22-185058.md","text":"https://secwatch.observer/filing/0001193125-22-185058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/0001193125-22-185058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/d322412d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:28:05.635710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}